Sign In
Buy MCRB
$5.62
-0.490 (-8.02%)
At Close: Jul 13, 2026
Seres Therapeutics' SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study
02:02pm, Friday, 10'th Jul 2026
Seres Therapeutics NASDAQ: MCRB reported results from an investigator-sponsored study of SER-155 in immune checkpoint inhibitor-related enterocolitis, or irEC, saying the data support further evaluati
Seres Therapeutics Posts Early Data for Cancer Therapy Complication
01:07pm, Wednesday, 08'th Jul 2026
Seres Therapeutics Inc. (NASDAQ:MCRB) on Wednesday reported topline results from an investigator-sponsored trial evaluating SER-155 in patients with immune-related enterocolitis (irEC), with most part
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript
80% of SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the Investigator-Sponsored Trial (IST) conducted by Memorial Sloan Kett
CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line res
Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
07:00am, Tuesday, 12'th May 2026
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C.
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
07:00am, Tuesday, 05'th May 2026
Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks Seres maintains operational focus on advancing live biother
Data highlight both SER-603's rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomar
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
07:00am, Monday, 20'th Apr 2026
Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration
Seres Therapeutics to Present at CARB-X Investor Day
07:00am, Thursday, 09'th Apr 2026
CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at th
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
07:00am, Thursday, 12'th Mar 2026
Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track
Seres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome Therapeutics Platform Prepared Remarks Transcript
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
04:05pm, Monday, 02'nd Mar 2026
Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs
Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash
08:29am, Thursday, 12'th Feb 2026
Seres Therapeutics Inc. (NASDAQ: MCRB) shares are down during Thursday's premarket session following the company's announcement of a strategic shift in its operations.
